The presence of human papillomavirus (HPV) DNA in cervical and vaginal scrapes was analyzed by the AffiProbe HPV test kit (Orion Corp., Orion Pharmaceutica, Helsinki, Finland), which is a 1-day solution hybridization test for HPV type 6/11, 16, or (9, 24, 29) . HPV type 16 and 18 DNAs are found in most cancer biopsy specimens (6, 11, 17, 30) , whereas many more types are present in cervical dysplasias (11, 18 
Human papillomaviruses (HPVs) cause infections of the genital tract, which can be subclinical or manifest as visible or flat condylomas. HPV infections are common; the annual incidence in Finland is 8% in young, sexually active female populations (23a) . HPV infection is considered a necessary but not a sufficient risk factor for the development of cervical cancer (9, 24, 29) . HPV type 16 and 18 DNAs are found in most cancer biopsy specimens (6, 11, 17, 30) , whereas many more types are present in cervical dysplasias (11, 18) .
Papillomavirus infections are a diagnostic problem because HPV cannot be cultivated in vitro and viral antigens cannot be reliably detected in clinical specimens. The presence of HPV is suspected by the presence of typical morphological changes in the epithelial cells detectable by cytology or histopathology. Specific diagnosis is, however, only possible by nucleic acid hybridization with type-specific probes (20) . Several DNA hybridization methods are in use, including Southern blot, dot blot, filter in situ, and in situ hybridization on tissue sections (21) .
We have developed a solution hybridization method, based on sandwich hybridization followed by affinity-based collection of the hybrids, for the detection of microbial DNA from crude clinical specimens (14, 16, 26) . One such test, the AffiProbe HPV test kit, is aimed at the detection of HPV DNA from genital scrapes. The specimen is divided into three aliquots for the detection HPV type 6/11, 16 AffiProbe HPV identification test. The AffiProbe HPV test kit allows for the simultaneous detection and typing of HPV types 6/11, 16, and 18. For that purpose, the AffiProbe specimen was divided into three 30-pÀl aliquots, each of which was treated separately with the specimen pretreatment solution to release and denature the viral DNA. The aliquots were subjected to hybridization with type-specific detector probes and the biotinylated capture DNA. The probes were labeled with "S isotope. After hybridization for 3 h at 65°C, the hybridization mixtures were transferred to microdilution wells coated with streptavidin. Binding was for 2 h at 37°C. The plates were then washed, and the labeled DNA that bound to hybrids was eluted with the elution solution and subjected to counting for 5 min in a scintillation counter (LKB Wallac, Turku, Finland). Positive and negative controls were included in each type-specific test series: three controls for background, two low-positive controls, and two high-positive controls. The cutoff of the test was set according to the mean of the low-positive standards, which, in all cases, was at least 1.5 times the mean of the background, i.e., negative control values. Eight test series were carried out. The mean of the cutoff-to-background ratio was 2.5 (range, 1.6 to 4.1) for HPV type 6/11-, 4.5 (range, 2.4 to 8.3) for HPV type 16-, and 6.0 (range, 1.9 to 11) for HPV type 18-specific tests.
ViraPap and ViraType tests. ViraPap and ViraType tests (Life Technologies Inc.) are intended for detection of DNAs of HPV types 6/11, 16/18, and 31/33/35, as groups, by using probe mixtures labeled with 32P isotope. The specimen DNA was dotted onto a nylon membrane and hybridized with a pool of the probe mixtures described above (ViraPap test). ViraPap-positive specimens were subsequently tested as three separate dots by using three group-specific probe mixtures in the hybridizations (ViraType test). Results were visualized by autoradiography. Typing results of positive specimens require from 4 days to 2 weeks, depending on the age of the probe.
Enzymatic amplification of HPV DNA by using type-specific primers (PCR). For the polymerase chain reaction (PCR) (13), DNA was isolated from the remaining aliquot of the AffiProbe specimen by phenol extraction and ethanol precipitation. The resulting DNA was dissolved in H20. PCR analysis for HPV types 6, 11, 16, and 18 used type-specific biotinylated primers followed by quantification in a hybridization test as described previously (8a, 25) . All primers were designed according to previously published sequences (3, 4, 22, 23) . As controls, we used linearized recombinant plasmid DNAs containing the appropriate HPV genome and (Fig. 1B) . The positive test results (see above) were derived from 36 cervical and 28 vaginal scrapes collected from a total of 49 patients. In 15 (31%) patients both the cervical and the vaginal scrapes were positive, in 20 patients only the cervical scrape was positive, and in 13 patients only the vaginal scrape was positive for HPV DNA (Table 1) . Double infections were found in seven specimens (Table 2 ). In one patient (patient 3), the double infection was detected in both cervical and vaginal scrapes, and in four patients, one of the HPV types was also found in a second site (vagina or cervix).
Correlation between the AffiProbe test and the control test in the detection of HPV DNA. The ViraPap and ViraType tests served as a reference method. For the comparison study, two simultaneously obtained cervical scrapes were available from 174 patients. A total of 18 specimens were positive and 129 specimens were negative for HPV types 6/11, 16, and 18 by both tests (Table 3) . Thus, the agreement between the two tests was 85%. Eleven AffiProbe-positive specimens were negative by the control test. Seven additional AffiProbe-positive specimens (five positive for HPV type 16 or 18 and two positive for HPV type 6/11; see Table  5 ) were suggested to contain HPV type 31/33/35 by the control test. Eighteen additional specimens that were nega- For PCR, material was available from 17 of 27 specimens. Of these, 6 were positive and 11 were negative for HPV DNA (Tables 5 and 6 ). In 2 specimens, the amount of DNA was at least 500 ng, and in 15 specimens it was less than 250 ng. In the group of specimens with a low yield of DNA, four specimens were positive, whereas both specimens with a substantial quantity of DNA were positive.
Of 11 AffiProbe-positive but ViraType-negative specimens (patients 1 to 11, Table 5 ), only 5 were available for repeat sampling. Three of these were positive. HPV DNA was also detected in either the vagina or vulva sample from two of the patients. The Papanicolaou smear was abnormal, suggesting HPV infection in four patients (Table 5) .
Of nine ViraType-positive but AffiProbe-negative specimens (patients 19 to 27; Table 6 ) only one was available for repeat sampling (patient 21), but the specimen was negative. HPV DNA was present in vaginal specimens from five patients, and the Papanicolaou smear suggested HPV infection in four patients.
Of seven patients with discrepant types (patients 12 to 18; Table 5 ), patient 12 was positive for HPV type 6/11 DNA, as was also detected in the vagina. On reexamination, HPV type 16 DNA was detected by both tests. In the other four patients (patients 15 to 18), the AffiProbe test showed low counts per minute. In three patients, DNA of HPV type 31/33/35 was also found in the vulval specimen, and in the fourth patient it was found in the vaginal specimen. In one patient (patient 15), the presence of HPV type 31/33/35 was confirmed by repeat sampling.
In conclusion, independent evidence, including cytology, supported the specificity of the AffiProbe HPV test in specimens from 7 of 11 patients (64%) that were negative by the ViraType assay. The specificity of the ViraType assay was suggested by similar analysis of specimens from seven Previous studies have shown variable agreement as to HPV DNA positivity in concurrently collected separate specimens (2, 8) . Furthermore, the HPV DNA detection rate is critically affected by the number of cells collected (12, 15, 28) . We therefore feel that the most plausible explanation for the discrepant results in this study was an uneven distribution of exfoliated cells into the two separate specimens. The specimens were not pooled and divided into two aliquots, because, according to the instructions of the test manufacturer, sampling is considered part of the identification kit.
In this study, HPV type 6/11, 16, 18, 31, 33, or 35 DNA was present in 63% of the cervical scrapes collected from women with cytologic atypia. The HPV DNA positivity as correlated with cytologic atypia was in the same range as that obtained by using Southern blotting for studying exfoliated cells (19, 28) . By studying vaginal scrapes, in addition to cervical scrapes, for the presence of HPV DNA, additional information is obtained. Genital HPV infections seem to be multifocal (10, 18) . It was recently reported (28) that the addition of cells from the posterior vagina to the cervical specimen increased the rate of HPV DNA detection significantly. The presence of HPV DNA detected by such combined specimens could regularly be confirmed by concurrent cervical punch biopsy (19) .
For our study, defined groups of mostly young females were selected. In these groups the incidence of HPV infections was high and the observed high number of falsenegative Papanicolaou smears was therefore not unexpected (5, 6, 27) . By collecting multiple genital scrapes, the total number of HPV DNA-positive patients increased from 63 to 76 (Table 1 ). The rate of HPV DNA-positive patients was 33% (31 patients) in the group of women visiting the emergency room, 60% (34 patients) in the patients visiting the abortion clinic, and 40% (11 patients) in the patients from the colposcopy clinic. Unexpectedly, the number of patients with cytological signs of HPV infection in the last group was small (37%). All HPV DNA-positive women with cervical dysplasia (10 patients) had positive cervical scrapes, but specimens from other genital sites were also frequently positive (Tables 5 and 6 ).
The sensitivities of the conventional HPV DNA detection methods are apparently sufficient for detecting HPV-associated lesions. When combined with a Papanicolaou smear, HPV DNA detection increases the probability of predicting histologically proven HPV lesions (19) . An important question in the diagnosis of HPV infection is the standardization of the assays to improve the interobserver reproducibility between different studies (1) . We 
